Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Other Non-Current Assets (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Other Non-Current Assets for 14 consecutive years, with $10.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Assets changed 0.0% year-over-year to $10.2 million, compared with a TTM value of $10.2 million through Sep 2025, changed 0.0%, and an annual FY2024 reading of $9000.0, down 99.94% over the prior year.
  • Other Non-Current Assets was $10.2 million for Q3 2025 at Fate Therapeutics, up from $9000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $15.2 million in Q2 2021 and bottomed at $9000.0 in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $8.4 million, with a median of $10.2 million recorded in 2024.
  • The sharpest move saw Other Non-Current Assets surged 169088.89% in 2022, then tumbled 99.94% in 2024.
  • Year by year, Other Non-Current Assets stood at $33000.0 in 2021, then changed by 0.0% to $33000.0 in 2022, then surged by 45890.91% to $15.2 million in 2023, then crashed by 99.94% to $9000.0 in 2024, then surged by 113533.33% to $10.2 million in 2025.
  • Business Quant data shows Other Non-Current Assets for FATE at $10.2 million in Q3 2025, $9000.0 in Q4 2024, and $10.2 million in Q3 2024.